English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Jorge Rico-Fontalvo1(ORCID: 0000-0002-2852-1241), Rodrigo Daza-Arnedo2(ORCID: 0000-0002-6295-4972), Maria Ximena Cardona-Blanco3(ORCID: 0000-0003-39187645), Victor Leal-Martínez4(ORCID: 0000-0003-1228-148X), Emilio Abuabara-Franco5(ORCID: 0000-0001-5098-6574), Nehomar Pajaro-Galvis6*(ORCID: 0000-0001-66821918), Jose Cabrales7(ORCID: 0000-0002-2584-6999), José Correa8(ORCID: 0000-0002-9736-4913), Manuel Cueto9(ORCID: 0000-0003-3915-7294), Amable Duran10(ORCID: 0000-0003-1895-1907), Alejandro Castellanos11(ORCID: 0000-0002-8822-6770), Javier Enamorado12(ORCID: 0000-0002-1828-7674), José Bohórquez13(ORCID: 2-9064-1068), Isabella Uparella14(ORCID: 0000-00032940-5362), Julio Zuñiga15(ORCID: 0000-0002-8018-6057), Abraham Chagui16(ORCID: 0000-0002-9818-2740), Alfonso Ramos17(ORCID: 0000-0003-2704-898X) and Luis Lara18(ORCID: 0000-0001-9186-1866)

SGLT2 Inhibitors and nephroprotection in diabetic kidney disease: From mechanisms of action to the latest evidence in the literature